Acadia postpones NDA for 'breakthrough' Parkinson's drug; Alchemia CEO exits;

@FierceBiotech: Amgen takes another stride in frenzied race toward the PCSK9 finish line. More | Follow @FierceBiotech

@JohnCFierce: Triple shot IL-13/IL-4 -- Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII. More | Follow @JohnCFierce

@DamianFierce: I had missed this excellent tick-tock of the last days of one Christopher A. Viehbacher. More | Follow @DamianFierce

> Acadia disappointed investors with the news that it will delay its planned NDA for the Parkinson's drug pimavanserin (Nuplazid). The biotech--which recently won 'breakthrough' status for the treatment--now plans to file in the first quarter of 2015. Its shares were down 3% this morning. Release

> Australia's Alchemia says CEO Thomas Liquard has left the company and will be temporarily replaced by non-executive chairman Tracie Ramsdale. Release

Medical Device News

@FierceMedDev: China FDA's new medical device importation regulations shorten review period. More | Follow @FierceMedDev

@VarunSaxena2: Device that performs hundreds of tests with a single drop of blood wins Nokia Sensing Xchallenge. More | Follow @VarunSaxena2

> Thync rolling out wearable, noninvasive device to elevate mood with fresh infusion of cash in tow. More

> Medtronic makes concessions to European regulator in bid to close Covidien deal. News

> OrthAlign secures $15M to launch new navigation system for orthopedic surgery. Article

Pharma News

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Story | Follow @EricPFierce

@CarlyHFierce: Dendreon bankruptcy weighs on cancer vaccine field. More | Follow @CarlyHFierce

> Take as directed? U.K. health service teams with academics, pharmacy on drug adherence. News

> Merck's head-to-head Vytorin trial might be surprisingly flattering. More

Biotech Research News

> Small human study will test a new approach to fighting diabetes. More

> Research team points to Sestrin 3 as a potential new target in diabetes. Article

> Harvard investigators prep an animal study of CRISPR Cas tech for HIV. Story

> Swiss team at ETH spotlights potential of a new antibiotic found in nature. More

> Genentech R&D team fixes a flawed approach to Alzheimer's. Report

Pharma Manufacturing News

> Cadila API plant slapped for faulty follow-up on stinking APIs. Article

> Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. Item

> Plant power outage zaps the juice from AMRI's earnings. More

> Dendreon, done in by expensive, complex manufacturing, files for bankruptcy. Story

> Fresenius expansion plans in Russia sidelined by political turmoil. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.